Compugen Cuts Q3 Loss

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that it had cut its net loss around 16 percent for the third-quarter, while the firm brought in no revenues for the period.

The Tel Aviv, Israel-based drug discovery informatics and drug development firm posted a net loss of $1.6 million, or $.05 per share, for the three-month period ended Sept. 30, compared to a net loss of $1.9 million, or $.06 per share, for the third quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.